13F-HR filed by Aquilo Capital Management, LLC
Aquilo Capital Management, LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 10 holding rows worth $160,453,237.
- Accession
- 0001591986-24-000002
- Filer
- CIK 1591986
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 10 entries on the cover page, a total value of $160,453,237 stated on the cover page (in dollars after the unit check, H1), rows summing to $160,453,237 with VALUE read as dollars as filed, 13F file number 028-18892. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS IN | 04280A100 | COM | 908,474 | $27,799,304 | dollars as filed | |
| BLUEPRINT MEDICINES CORP | 09627Y109 | COM | 254,827 | $23,505,242 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 881,337 | $22,438,840 | dollars as filed | |
| ARVINAS INC | 04335A105 | COM | 489,153 | $20,133,537 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 1,043,284 | $18,121,843 | dollars as filed | |
| SPDR SER TR | 78464A870 | S&P BIOTECH | 200,000 | $17,858,000 | dollars as filed | put |
| REGENXBIO INC | 75901B107 | COM | 802,424 | $14,403,511 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 355,109 | $9,765,498 | dollars as filed | |
| REPARE THERAPEUTICS INC | 760273102 | COM | 633,271 | $4,622,878 | dollars as filed | |
| SUTRO BIOPHARMA INC | 869367102 | COM | 420,649 | $1,804,584 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001591986-24-000002 | this filing | 2024-02-14 | acceptance time not in the bulk data set |